Short peptide, and applications of compositions thereof in treatment/prevention of diabetes and related diseases thereof

A composition and technology for diabetes, applied in the field of peptides, can solve the problems of patients' health side effects, inability to effectively treat or improve diabetes and its complications, etc.

Pending Publication Date: 2020-02-04
TUNGHAI UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term use of these drugs for the treatment of diabetes or its complications will have side effects on the patient's health, and cannot effectively treat or improve the effect of diabetes and its complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Short peptide, and applications of compositions thereof in treatment/prevention of diabetes and related diseases thereof
  • Short peptide, and applications of compositions thereof in treatment/prevention of diabetes and related diseases thereof
  • Short peptide, and applications of compositions thereof in treatment/prevention of diabetes and related diseases thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: Preparation of short peptides

[0056] Prepare the disclosed IF and DF peptides of the present invention by chemical synthesis, and confirm the purity of the IF and DF peptides by HPLC, the results are as follows figure 1 and figure 2 As shown, it was shown that the peptides prepared by the chemical synthesis method had high purity.

Embodiment 2

[0057] Example 2: Cell Culture

[0058] H9c2 cells (ATCC, CRL-1446) were purchased from the American Type Culture Collection (Rockville, MD). H9c2 cells were cultured in DMEM medium (DMEM) supplemented with 2 mM glutamine, 10% bovine serum (Cosmic Calf Serum), 100 U / mL penicillin and streptomycin, and 1 mM sodium pyruvate under the following conditions: 37°C, Moist air (5% carbon dioxide).

Embodiment 3

[0059] Example 3: Cell Experiment

[0060] H9c2 cells were divided into several groups, including:

[0061] The control group was cultured with normal glucose (22mM) medium;

[0062] High glucose group: cultured in medium containing high glucose (33mM);

[0063] Low-dose IF peptide group: cultured in medium containing high glucose (33mM) and 5μg of IF peptide;

[0064] High-dose IF peptide group: cultured in medium containing high glucose (33mM) and 10μg of IF peptide;

[0065] Low-dose DF peptide group: cultured in medium containing high glucose (33mM) and 5μg of IF peptide;

[0066] High-dose DF peptide group: cultured in medium containing high glucose (33 mM) and 10 μg of IF peptide.

[0067] Cells in each group were cultured in their conditions for 24 hours before subsequent analysis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The inventin discloses a short peptide, which has the effect of relieving necrocytosis, cell apoptosis and / or cell hypertrophy caused by hyperglycemia and recovering the proliferation effect of isletcells due to diabetes; therefore, by dosing a patient suffered from diabetes or hyperglycemia with the peptide in the invention, the function of effectively treating the diabetes or complications thereof; wherein, the diabetes complications may include diabetic cardiopathy, diabetic vasculopathy, diabetic hepatic pathological changes, diabetic nephropathy, pancreatic necrosis, etc.

Description

technical field [0001] The present invention relates to the use of peptides, in particular to the use of a short peptide and its composition for treating / preventing diabetes and related diseases. Background technique [0002] Diabetes mellitus is a metabolic disease that keeps the patient's blood sugar higher than the standard value for a long time. Diabetes will not only keep patients in a state of high blood sugar, but also cause various parts of the body or organs to be affected by high blood sugar and cause diseases, such as retinopathy, kidney disease, difficult to heal wounds, cardiovascular disease, etc. [0003] Diabetic cardiomyopathy is a heart disease that occurs in patients with diabetes and increases mortality in diabetic patients. The causes and heart conditions of diabetic cardiomyopathy are different from other heart diseases, such as hypertensive heart disease or coronary heart disease. In general, diabetic cardiomyopathy comprises a series of interrelated...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C07K5/062A61K38/08A61K38/05A61P3/10A61P9/00A61P1/16A61P13/12A61P5/50
CPCC07K7/08C07K5/06034A61K38/08A61K38/05A61P3/10A61P9/00A61P1/16A61P13/12A61P5/50A61K2300/00
Inventor 林万登
Owner TUNGHAI UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap